参考文献/References:
[1]Siegel KR,Ali MK,Ackermann RT,et al.Evaluating Natural Experiments that Impact the Diabetes Epidemic: an Introduction to the NEXT-D3 Network[J].Curr Diab Rep,2022,22(8):393-403.[2]Nnakenyi ID,Nnakenyi EF,Parker EJ,et al.Relationship between glycaemic control and lipid profile in type 2 diabetes mellitus patients in a low-resource setting[J].Pan Afr Med J,2022,41:281.[3]Bejoy J,Farry JM,Peek JL,et al.Podocytes derived from human induced pluripotent stem cells: characterization, comparison, and modeling of diabetic kidney disease[J].Stem Cell Research & Therapy,2022,13(1):355.[4]Zhang W,Liu X,Dong Z,et al.New Diagnostic Model for the Differentiation of Diabetic Nephropathy From Non-Diabetic Nephropathy in Chinese Patients[J].Front Endocrinol (Lausanne),2022,13:913021.[5]Gomez-Virgilio L,Silva-Lucero MD,Flores-Morelos DS,et al.Autophagy: A Key Regulator of Homeostasis and Disease: An Overview of Molecular Mechanisms and Modulators[J].Cells,2022,11(15):2262.[6]de Sá JR,Rangel EB,Canani LH,et al.The 2021-2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD[J].Diabetol Metab Syndr,2022,14(1):81.[7]Rajbhandari A,Bhusal U,Shrestha DB,et al.End Stage Renal Disease among Patients Undergoing Haemodialysis at a Tertiary Care Centre: A Descriptive Cross-sectional Study[J].Journal of Nepal Medical Association,2022,60(249):448-452.[8]Hofherr A,Williams J,Gan L,et al.Targeting inflammation for the treatment of Diabetic Kidney Disease: a five-compartment mechanistic model[J].BMC Nephrology,2022,23(1):208.[9]Thomas B.The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps[J].Current Diabetes Reports,2019,19(4):18.[10]Yang X,Yang Y.Ferroptosis as a Novel Therapeutic Target for Diabetes and Its Complications[J].Frontiers in Endocrinology,2022,13:853822.[11]Akhtar M,Taha NM,Nauman A,et al.Diabetic Kidney Disease:Past and Present[J].Adv Anat Pathol,2020,27(2):87-97.[12]de Boer IH,Caramori ML,Chan JCN,et al.Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment[J].Kidney Int,2020,98(4):839-848.[13]Martínez-Castelao A,Soler MJ,GórrizTeruel JL,et al.Optimizing the timing of nephrology referral for patients with diabetic kidney disease[J].Clinical Kidney Journal,2021,14(1):5-8.[14]Looker HC,Mauer M,Nelson RG.Role of Kidney Biopsies for Biomarker Discovery in Diabetic Kidney Disease[J].Advances in Chronic Kidney Disease,2018,25(2):192-201.[15]Cheng Y,Shang J,Liu D,et al.Development and validation of a predictive model for the progression of diabetic kidney disease to kidney failure[J].Renal failure,2020,42(1):550-559.[16]中华医学会肾脏病学分会专家组.终末期糖尿病肾脏病肾替代治疗的中国指南[J].中华肾脏病杂志,2022,38(1):62-75.[17]Fu H,Liu S,Bastacky SI,et al.Diabetic kidney diseases revisited: A new perspective for a new era[J].Molecular Metabolism,2019,30:250-263.[18]Mitchell NS,Scialla JJ,Yancy WS.Are low‐carbohydrate diets safe in diabetic and nondiabetic chronic kidney disease?[J].Annals of the New York Academy of Sciences,2019,1461(1):25-36.[19]Wu J,Liu D,Yang L,et al.Association Between Serum Homocysteine Levels and Severity of Diabetic Kidney Disease in 489 Patients with Type 2 Diabetes Mellitus: A Single-Center Study[J].Medical Science Monitor,2022,28:e936323.[20]Futrakul N,Futrakul P.Biomarker for early renal microvascular and diabetic kidney diseases[J].Ren Fail,2017,39(1):505-511.[21]Lin Y,Chang Y,Yang S,et al.Update of pathophysiology and management of diabetic kidney disease[J].Journal of the Formosan Medical Association,2018,117(8):662-675.[22]Balmer LA,Whiting R,Rudnicka C,et al.Genetic characterization of early renal changes in a novel mouse model of diabetic kidney disease[J].Kidney International,2019,96(4):918-926.[23]Rodriguez F,Lee DJ,Gad SS,et al.Real-World Diagnosis and Treatment of Diabetic Kidney Disease[J].Advances in Therapy,2021,38(8):4425-4441.[24]Yang J,Liu Z.Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy[J].Frontiers in Endocrinology,2022,13:816400.[25]Tserga A,Pouloudi D,Saulnier-Blache JS,et al.Proteomic Analysis of Mouse Kidney Tissue Associates Peroxisomal Dysfunction with Early Diabetic Kidney Disease[J].Biomedicines,2022,10(2):216.[26]Lu H,Dai W,He L.Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease[J].Diabetes Metab Syndr Obes,2021,14:329-344.[27]El-Azab MF,Al-Karmalawy AA,Antar SA,et al.A novel role of Nano selenium and sildenafil on streptozotocin-induced diabetic nephropathy in rats by modulation of inflammatory, oxidative, and apoptotic pathways[J].Life Sciences,2022,303:120691.[28]Matsusaka T,Sandgren E,Shintani A,et al.Podocyte injury damages other podocytes[J].J Am Soc Nephrol,2011,22(7):1275-1285.[29]Yoshibayashi M,Kume S,Yasuda-Yamahara M,et al.Protective role of podocyte autophagy against glomerular endothelial dysfunction in diabetes[J].Biochemical and Biophysical Research Communications,2020,525(2):319-325.[30]Dusabimana T,Kim SR,Park EJ,et al.P2Y2R contributes to the development of diabetic nephropathy by inhibiting autophagy response[J].Molecular Metabolism,2020,42:101089.[31]Teh YM,Mualif SA,Lim SK.A comprehensive insight into autophagy and its potential signaling pathways as a therapeutic target in podocyte injury[J].The International Journal of Biochemistry & Cell Biology,2022,143:106153.[32]Bhatia D,Choi ME.Autophagy in kidney disease: Advances and therapeutic potential[J].Progress in molecular biology and translational science,2020,172:107-133.[33]Hou Y,Lin S,Qiu J,et al.NLRP3 inflammasome negatively regulates podocyte autophagy in diabetic nephropathy[J].Biochemical and Biophysical Research Communications,2020,521(3):791-798.[34]Lin Q,Banu K,Ni Z,et al.Podocyte Autophagy in Homeostasis and Disease[J].Journal of Clinical Medicine,2021,10(6):1184.[35]Yasuda-Yamahara M,Kume S,Maegawa H.Roles of mTOR in Diabetic Kidney Disease[J].Antioxidants,2021,10(2):321.[36]Audzeyenka I,Rogacka D,Piwkowska A,et al.Viability of primary cultured podocytes is associated with extracellular high glucose-dependent autophagy downregulation[J].Molecular and Cellular Biochemistry,2017,430(1-2):11-19.[37]Liu W,Huang W,Ye L,et al.The activity and role of autophagy in the pathogenesis of diabetic nephropathy[J].European review for medical and pharmacological sciences,2018,22(10):3182-3189.[38]Liu L,Yang L,Chang B,et al.The protective effects of rapamycin on cell autophagy in the renal tissues of rats with diabetic nephropathy via mTOR-S6K1-LC3II signaling pathway[J].Ren Fail,2018,40(1):492-497.[39]Yu S,Ren Q,Yu L,et al.Role of autophagy in Puromycin Aminonucleoside-induced podocyte apoptosis[J].J Recept Signal Transduct Res,2020,40(3):273-280.[40]Li Q,Zeng Y,Jiang Q,et al.Role of mTOR signaling in the regulation of high glucose-induced podocyte injury[J].Experimental and therapeutic medicine,2019,17(4):2495-2502.[41]Fang L,Zhou Y,Cao H,et al.Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury[J].PLoS One,2013,8(4):e60546.[42]Yu S,Ren Q,Chen J,et al.Rapamycin reduces podocyte damage by inhibiting the PI3K/AKT/mTOR signaling pathway and promoting autophagy[J].European Journal of Inflammation,2022,20:1721727X-2210817X.[43]Gonzalez CD,CarroNegueruela MP,NicoraSantamarina C,et al.Autophagy Dysregulation in Diabetic Kidney Disease: From Pathophysiology to Pharmacological Interventions[J].Cells,2021,10(9):2497.[44]Xu Y,Zhou Q,Xin W,et al.Autophagy downregulation contributes to insulin resistance mediated injury in insulin receptor knockout podocytesin vitro[J].Peer J,2016,4:e1888.[45]Wang D,Jin M,Zhao X,et al.FGF1ΔHBS ameliorates chronic kidney disease via PI3K/AKT mediated suppression of oxidative stress and inflammation[J].Cell Death & Disease,2019,10(6):464.[46]Grahammer F,Huber TB,Artunc F.Role of mTOR Signaling for Tubular Function and Disease[J].Physiology (Bethesda),2021,36(6):350-358.[47]Liu N,Xu L,Shi Y,et al.Podocyte Autophagy: A Potential Therapeutic Target to Prevent the Progression of Diabetic Nephropathy[J].Journal of Diabetes Research,2017,2017:1-6.[48]Chen Y,Zhao X,Li J,et al.Amino acid starvation promotes podocyte autophagy through mammalian target of rapamycin inhibition and transcription factor EB activation[J].Molecular medicine reports,2018,18(5):4342-4348.[49]Hou B,Li Y,Li X,et al.HGF protected against diabetic nephropathy via autophagy-lysosome pathway in podocyte by modulating PI3K/Akt-GSK3β-TFEB axis[J].Cellular Signalling,2020,75:109744.[50]Sun Y,Deng M,Ke X,et al.Epidermal Growth Factor Protects Against High Glucose-Induced Podocyte Injury Possibly via Modulation of Autophagy and PI3K/AKT/mTOR Signaling Pathway Through DNA Methylation[J].Diabetes Metab Syndr Obes,2021,14:2255-2268.[51]Chen S,Chen L,Jiang H.Integrated Bioinformatics and Clinical Correlation Analysis of Key Genes, Pathways, and Potential Therapeutic Agents Related to Diabetic Nephropathy[J].Disease Markers,2022,2022:1-13.[52]Yoshihara E.TXNIP/TBP-2: A Master Regulator for Glucose Homeostasis[J].Antioxidants,2020,9(8):765.[53]Mandala A,Das N,Bhattacharjee S,et al.Thioredoxin interacting protein mediates lipid-induced impairment of glucose uptake in skeletal muscle[J].Biochem Biophys Res Commun,2016,479(4):933-939.[54]Chen N,Mu L,Yang Z,et al.Carbohydrate response element-binding protein regulates lipid metabolism via mTOR complex1 in diabetic nephropathy[J].J Cell Physiol,2021,236(1):625-640.[55]Du C,Wu M,Liu H,et al.Thioredoxin-interacting protein regulates lipid metabolism via Akt/mTOR pathway in diabetic kidney disease[J].The International Journal of Biochemistry & Cell Biology,2016,79:1-13.[56]Lin P,Pan Y,Chen H,et al.Key genes of renal tubular necrosis: a bioinformatics analysis[J].Translational Andrology and Urology,2020,9(2):654-664.[57]Mohamed R,Jayakumar C,Ranganathan PV,et al.Kidney proximal tubular epithelial-specific overexpression of netrin-1 suppresses inflammation and albuminuria through suppression of COX-2-mediated PGE2 production in streptozotocin-induced diabetic mice[J].Am J Pathol,2012,181(6):1991-2002.[58]González LM,Robles NR,Mota-Zamorano S,et al.Genetic Variants in PGE2 Receptors Modulate the Risk of Nephrosclerosis and Clinical Outcomes in These Patients[J].J Pers Med,2021,1(8):772.[59]Xu J,Deng Y,Wang Y,et al.SPAG5‐AS1 inhibited autophagy and aggravated apoptosis of podocytes via SPAG5/AKT/mTOR pathway[J].Cell Proliferation,2020,53(2):e12738.[60]Li F,Li L,Hao J,et al.Src Homology 2 Domain-Containing Inositol 5’-Phosphatase Ameliorates High Glucose-Induced Extracellular Matrix Deposition via the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway in Renal Tubular Epithelial Cells[J].J Cell Biochem,2017,118(8):2271-2284.[61]Li F,Li L,Cheng M,et al.SHIP, a novel factor to ameliorate extracellular matrix accumulation via suppressing PI3K/Akt/CTGF signaling in diabetic kidney disease[J].Biochemical and Biophysical Research Communications,2017,482(4):1477-1483.[62]Grasso D,Renna FJ,Vaccaro MI.Initial Steps in Mammalian Autophagosome Biogenesis[J].Frontiers in Cell and Developmental Biology,2018,6:146.[63]Kaushal GP,Chandrashekar K,Juncos LA,et al.Autophagy Function and Regulation in Kidney Disease[J].Biomolecules,2020,10(1):100.[64]Li F,Li L,Cheng M,et al.SHIP, a novel factor to ameliorate extracellular matrix accumulation via suppressing PI3K/Akt/CTGF signaling in diabetic kidney disease[J].Biochem Biophys Res Commun,2017,482(4):1477-1483.
相似文献/References:
[1]陈淑雯.肾衰宁联合科素亚治疗早期糖尿病肾病的临床观察[J].医学信息,2018,31(05):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
CHEN Shu-wen.Clinical Observation on Early Diabetic Nephropathy Treated by Shenshuaining Combined with Kosu[J].Journal of Medical Information,2018,31(22):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
[2]何丽杰.中西医治疗糖尿病肾病的临床效果分析[J].医学信息,2018,31(10):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
HE Li-jie.Clinical Effect Analysis of Diabetic Nephropathy Treated by Chinese and Western Medicine[J].Journal of Medical Information,2018,31(22):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
[3]贺 伟,高 峰.24 h尿微量白蛋白、血清胱抑素C水平与血清肌酐、尿素水平在2型糖尿病肾病早期诊断的意义[J].医学信息,2018,31(11):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
HE Wei,GAO Feng.The Significance of 24 h Urinary Microalbumin,Serum Cystatin C and Serum Creatinine and Urea Levels in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2018,31(22):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
[4]黄秋菊.胱抑素C及脂蛋白α在早期糖尿病肾病诊断中的价值研究[J].医学信息,2018,31(14):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
HUANG Qiu-ju.The Value of Cystatin C and Lipoprotein α in the Diagnosis of Early Diabetic Nephropathy[J].Journal of Medical Information,2018,31(22):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
[5]陆新虹,温玉洁,胡 欣,等.α-硫辛酸对2型糖尿病肾病患者
血清内脂素的影响研究[J].医学信息,2018,31(14):60.[doi:10.3969/j.issn.1006-1959.2018.14.019]
LU Xin-hong,WEN Yu-jie,HU Xin,et al.Effect of α-lipoic Acid on Serum Visfatin in Patients with
Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2018,31(22):60.[doi:10.3969/j.issn.1006-1959.2018.14.019]
[6]肖学秀.益气活血汤联合西药治疗早期糖尿病肾病的临床观察[J].医学信息,2019,32(02):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
XIAO Xue-xiu.Clinical Observation of Yiqi Huoxue Decoction Combined with Western Medicine in Treating Earlyn Diabetic Nephropathy[J].Journal of Medical Information,2019,32(22):166.[doi:10.3969/j.issn.1006-1959.2019.02.051]
[7]郑小鹏,辛 华.糖尿病肾病研究进展[J].医学信息,2018,31(16):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
ZHENG Xiao-peng,XIN Hua.Progress in the Study of Diabetic Nephropathy[J].Journal of Medical Information,2018,31(22):26.[doi:10.3969/j.issn.1006-1959.2018.16.008]
[8]李志俊,王 利,王 浩.姜黄素改善糖尿病肾病的作用机制研究[J].医学信息,2018,31(24):35.[doi:10.3969/j.issn.1006-1959.2018.24.010]
LI Zhi-jun,WANG Li,WANG Hao.Study on the Mechanism of Curcumin in Improving Diabetic Nephropathy[J].Journal of Medical Information,2018,31(22):35.[doi:10.3969/j.issn.1006-1959.2018.24.010]
[9]张国艳,张佳田,隋洪玉.糖尿病肾病大鼠动物模型建立及INF-α干预机制研究[J].医学信息,2019,32(05):101.[doi:10.3969/j.issn.1006-1959.2019.05.030]
ZHANG Guo-yan,ZHANG Jia-tian,SUI Hong-yu.Establishment of Animal Model of Diabetic Nephropathy Rats and Study of INF-α Intervention Mechanism[J].Journal of Medical Information,2019,32(22):101.[doi:10.3969/j.issn.1006-1959.2019.05.030]
[10]吴怡琪,卢 文.皮肤AGEs荧光检测对糖尿病肾病的临床意义[J].医学信息,2019,32(06):101.[doi:10.3969/j.issn.1006-1959.2019.06.031]
WU Yi-qi,LU Wen.Clinical Significance of Skin AGEs Fluorescence Detection in Diabetic Kidney Disease[J].Journal of Medical Information,2019,32(22):101.[doi:10.3969/j.issn.1006-1959.2019.06.031]